4CPS-144 Abstract withdrawn

Background and Importance According to the pharmacotherapeutic guide of our health system; monoclonal antibodies (MCA) against calcitonin gene-related peptide (CGRP) were started for a maximum period of 1 year, and could be restarted if necessary after a therapeutic break. Aim and Objectives To describe which MCA was used to treat chronic migraine during the first and subsequent treatment cycles, the dosage used and the therapeutic rest time experienced in a tertiary hospital. Material and Methods All patients treated with an MCA against CGRP in a tertiary hospital from August 2020 to August 2022 were analysed. The variables were collected: sex, age, treatment during the first and subsequent years, duration of treatment, dosage, therapeutic rest time and adherence. Data were extracted from the outpatient module (Farmatools®) and the computerised electronic history (Jimena®). The data collection and analysis was carried out in an Excel table of our own creation. Results 74 patients (N=74) were included, with a median age of 46±12 years. 58 women (78.38%). During the first cycle, 60 (81.08%) started with erenumab and 14 (18.91%) with galcanezumab. Of the patients who started with erenumab, 66 (89,19%) maintained the dose of 140 mg/ 4 weeks and only 8 (10.81%) maintained the dose of 70 mg/ 4 weeks. On average, this dose was maintained for 3.51±1.64 doses before escalating. 43 (58.10%) have restarted treatment after completing the first cycle: 21 (48.84%) with erenumab and 22 (51.16%) with galcanezumab. On average, patients were without treatment for 183,60 days. Only 2 (4.65%) had a therapeutic break of less than 90 days. Conclusion and Relevance Most of the patients treated have been women. During the first cycle, they were mostly treated with erenumab, a high percentage with a dose of 140 mg/4 weeks. Almost half of the patients had to restart after a therapeutic break. The therapeutic break lasted on average around 6 months. Practically half restarted with the same drug as the first cycle. These data will allow us to analyse them in the future and modify our therapeutic attitude to improve care for our patients. References and/or Acknowledgements Conflict of Interest No conflict of interest.